EntryPoint Capital’s Pulse Biosciences PLSE Stock Holding History

EntryPoint Capital’s Portfolio PLSE Stock Details PLSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,364	Closed	-$156K	–	834
2025 Q2	$156K	Buy	+10,364	New	+$172K	0.08%	528

Other funds holding PLSE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GAM

Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

EntryPoint Capital's PLSE Position: Q3 2025 in Review

EntryPoint Capital sold out of Pulse Biosciences (PLSE) in Q3 2025, closing a stake of 10,364 shares — an estimated $156K sold.

EntryPoint Capital first reported a position in PLSE in Q2 2025 and held it in 1 quarter. The position peaked at $156K in Q2 2025. 84 funds tracked by Wall St. Rank hold PLSE as of Q3 2025.

EntryPoint Capital reported no remaining Pulse Biosciences position as of Q3 2025 after selling out during the quarter.
EntryPoint Capital sold 10,364 Pulse Biosciences shares in Q3 2025, an estimated $156K.
EntryPoint Capital first reported a position in Pulse Biosciences in Q2 2025 and held it in 1 quarter.
EntryPoint Capital's Pulse Biosciences position peaked at $156K in Q2 2025.
84 funds tracked by Wall St. Rank held Pulse Biosciences as of Q3 2025.

Based on EntryPoint Capital's 13F filing for Q3 2025, filed 13 Nov 2025.